Citations

Showing 10 of 108081 citations.

Intractable Epilepsy and Progressive Cognitive Decline in a Young Man
Cohen, Alexander L. , Jones, Lyell K. , Parisi, Joseph E. , Klaas, James P. , Jones, Lyell K , Cohen, Alexander

Mayo Clinic

JAMA Neurology | April 7, 2017 | Volume: 74 | Issue: 6 | Pages: 737

10.1001/jamaneurol.2016.3195 | PMID 28384730 Get It

A Diagnostic Marker to Discriminate Childhood Apraxia of Speech From Speech Delay: II. Validity Studies of the Pause Marker
Shriberg, Lawrence D., Fourakis, Marios, Jakielski, Kathy J., Hall, Sheryl D., Karlsson, Heather B., Mabie, Heather L. , McSweeny, Jane L., Tilkens, Christie M., Strand, Edythe A. , Wilson, David L.

Mayo Clinic

Journal of Speech, Language, and Hearing Research | April 7, 2017 | Volume: 60 | Issue: 4 | Pages: No page available

10.1044/2016_jslhr-s-15-0297 | PMID 28384803 Get It

Purpose The purpose of this 2nd article in this supplement is to report validity support findings for the Pause Marker (PM), a proposed single-sign diagnostic marker of childhood apraxia of speech (CAS). Method PM scores and additional perceptual and acoustic measures were obtained from 296 participants in cohorts with idiopathic and neurogenetic CAS, adult-onset apraxia of speech and primary progressive apraxia of speech, and idiopathic speech delay. Results Adjusted for questionable specificity disagreements with a pediatric Mayo Clinic diagnostic standard, the estimated sensitivity and specificity, respectively, of the PM were 86.8% and 100% for the CAS cohort, yielding positive and negative likelihood ratios of 56.45 (95% confidence interval [CI]: [1.15, 2763.31]) and 0.13 (95% CI [0.06, 0.30]). Specificity of the PM for 4 cohorts totaling 205 participants with speech delay was 98.5%. Conclusion These findings are interpreted as providing support for the PM as a near-conclusive diagnostic marker of CAS.
A Diagnostic Marker to Discriminate Childhood Apraxia of Speech From Speech Delay: IV. The Pause Marker Index
Shriberg, Lawrence D., Fourakis, Marios, Jakielski, Kathy J., Hall, Sheryl D., Karlsson, Heather B., Mabie, Heather L. , McSweeny, Jane L., Tilkens, Christie M., Strand, Edythe A. , Wilson, David L.

Mayo Clinic

Journal of Speech, Language, and Hearing Research | April 7, 2017 | Volume: 60 | Issue: 4 | Pages: No page available

10.1044/2016_jslhr-s-16-0149 | PMID 28384662 Get It

Purpose Three previous articles provided rationale, methods, and several forms of validity support for a diagnostic marker of childhood apraxia of speech (CAS), termed the pause marker (PM). Goals of the present article were to assess the validity and stability of the PM Index (PMI) to scale CAS severity. Method PM scores and speech, prosody, and voice precision-stability data were obtained for participants with CAS in idiopathic, neurogenetic, and complex neurodevelopmental disorders; adult-onset apraxia of speech consequent to stroke and primary progressive apraxia; and idiopathic speech delay. Three studies were completed including criterion and concurrent validity studies of the PMI and a temporal stability study of the PMI using retrospective case studies. Results PM scores were significantly correlated with other signs of CAS precision and stability. The best fit of the distribution of PM scores to index CAS severity was obtained by dividing scores into 4 ordinal severity classifications: mild, mild-moderate, moderate-severe, and severe. Severity findings for the 4 classifications and retrospective longitudinal findings from 8 participants with CAS supported the validity and stability of the PMI. Conclusion Findings support research and clinical use of the PMI to scale the severity of CAS.
A Diagnostic Marker to Discriminate Childhood Apraxia of Speech From Speech Delay: I. Development and Description of the Pause Marker
Shriberg, Lawrence D., Fourakis, Marios, Jakielski, Kathy J., Hall, Sheryl D., Karlsson, Heather B., Mabie, Heather L. , McSweeny, Jane L., Tilkens, Christie M., Strand, Edythe A. , Wilson, David L.

Mayo Clinic

Journal of Speech, Language, and Hearing Research | April 7, 2017 | Volume: 60 | Issue: 4 | Pages: No page available

10.1044/2016_jslhr-s-15-0296 | PMID 28384779 Get It

Purpose The goal of this article (PM I) is to describe the rationale for and development of the Pause Marker (PM), a single-sign diagnostic marker proposed to discriminate early or persistent childhood apraxia of speech from speech delay. Method The authors describe and prioritize 7 criteria with which to evaluate the research and clinical utility of a diagnostic marker for childhood apraxia of speech, including evaluation of the present proposal. An overview is given of the Speech Disorders Classification System, including extensions completed in the same approximately 3-year period in which the PM was developed. Results The finalized Speech Disorders Classification System includes a nosology and cross-classification procedures for childhood and persistent speech disorders and motor speech disorders (Shriberg, Strand, & Mabie, 2017). A PM is developed that provides procedural and scoring information, and citations to papers and technical reports that include audio exemplars of the PM and reference data used to standardize PM scores are provided. Conclusions The PM described here is an acoustic-aided perceptual sign that quantifies one aspect of speech precision in the linguistic domain of phrasing. This diagnostic marker can be used to discriminate early or persistent childhood apraxia of speech from speech delay.
A Diagnostic Marker to Discriminate Childhood Apraxia of Speech From Speech Delay: III. Theoretical Coherence of the Pause Marker with Speech Processing Deficits in Childhood Apraxia of Speech
Shriberg, Lawrence D., Fourakis, Marios, Jakielski, Kathy J., Hall, Sheryl D., Karlsson, Heather B., Mabie, Heather L. , McSweeny, Jane L., Tilkens, Christie M., Strand, Edythe A. , Wilson, David L.

Mayo Clinic

Journal of Speech, Language, and Hearing Research | April 7, 2017 | Volume: 60 | Issue: 4 | Pages: No page available

10.1044/2016_jslhr-s-15-0298 | PMID 28384751 Get It

Purpose Previous articles in this supplement described rationale for and development of the pause marker (PM), a diagnostic marker of childhood apraxia of speech (CAS), and studies supporting its validity and reliability. The present article assesses the theoretical coherence of the PM with speech processing deficits in CAS. Method PM and other scores were obtained for 264 participants in 6 groups: CAS in idiopathic, neurogenetic, and complex neurodevelopmental disorders; adult-onset apraxia of speech (AAS) consequent to stroke and primary progressive apraxia of speech; and idiopathic speech delay. Results Participants with CAS and AAS had significantly lower scores than typically speaking reference participants and speech delay controls on measures posited to assess representational and transcoding processes. Representational deficits differed between CAS and AAS groups, with support for both underspecified linguistic representations and memory/access deficits in CAS, but for only the latter in AAS. CAS–AAS similarities in the age–sex standardized percentages of occurrence of the most frequent type of inappropriate pauses ( abrupt ) and significant differences in the standardized occurrence of appropriate pauses were consistent with speech processing findings. Conclusions Results support the hypotheses of core representational and transcoding speech processing deficits in CAS and theoretical coherence of the PM's pause-speech elements with these deficits.
Insights into the Functional Anatomy Behind the PREEMPT Injection Paradigm: Guidance on Achieving Optimal Outcomes
Blumenfeld, Andrew , Silberstein, Stephen D., Aurora, Sheena K. , Brin, Mitchell F. , Binder, William J. , Dodick, David W.

Mayo Clinic

Headache: The Journal of Head and Face Pain | April 7, 2017 | Volume: 57 | Issue: 5 | Pages: 766-777

10.1111/head.13074 | PMID 28387038 Get It

Objective To provide clinically relevant insights on the identification of the muscles and techniques involved in the safe and effective use of onabotulinumtoxinA for chronic migraine prophylaxis. Background Although guidance on the use of onabotulinumtoxinA for chronic migraine is available, based on the Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) clinical program, clinical experience has shown that insufficient understanding of the anatomy and function of the head and neck muscles may lead to undesirable outcomes and suboptimal efficacy. Design/Methods Each muscle involved in the standardized PREEMPT injection paradigm is reviewed with a thorough description of each muscle's anatomy (ie, muscle description and location, innervation, vascular supply) and function. Key insights based on clinical experience are also provided to help improve outcomes. Results The identification of the muscles in the PREEMPT injection paradigm should be based on each patient's unique anatomy and injections should be administered using the advised techniques. A thorough examination of the patient prior to treatment is also critical to determine if any preexisting conditions may increase the risk for unwanted outcomes and appropriate expectations should be communicated. Conclusions Thorough knowledge of the functional anatomy of the muscles involved in the standardized PREEMPT injection paradigm is critical to achieve the efficacy and safety observed in clinical trials. In addition, it is important to assess a patient's baseline condition to anticipate the risk for unwanted outcomes that may result from treatment.
Transscrotal Near Infrared Spectroscopy as a Diagnostic Test for Testis Torsion in Pediatric Acute Scrotum: A Prospective Comparison to Gold Standard Diagnostic Test Study
Schlomer, Bruce J., Keays, Mélise , Grimsby, Gwen M. , Granberg, Candace F. , DaJusta, Daniel , Menon, Vani S. , Ostrov, Lauren , Sheth, Kunj , Hill, Martinez, Sanchez, Emma, Harrison, Clanton B., Jacobs, Micah A. , Huang, Rong , Burgu, Berk , Hennes, Halim , Baker, Linda A.

Mayo Clinic

Journal of Urology | April 6, 2017 | Volume: 198 | Issue: 3 | Pages: 694-701

10.1016/j.juro.2017.03.134 | PMID 28392394 Get It

Genotypic analysis of Tropheryma whipplei from patients with Whipple disease in the Americas
Rollin, Dominique , Paddock, Christopher D. , Pritt, Bobbi S. , Cunningham, Scott A. , Denison, Amy M. , Rollin, Dominique C , Pritt, Bobbi S , Cunningham, Scott A

Mayo Clinic

Journal of Clinical Pathology | April 6, 2017 | Volume: 70 | Issue: 10 | Pages: 891-895

10.1136/jclinpath-2017-204382 | PMID 28385924 Get It

Tropheryma whipplei, the agent of Whipple disease, causes a rare bacterial disease that may be fatal if not treated. The classical form of the disease includes diarrhoea, weight loss, arthritis, endocarditis and neurological manifestations. Genotyping studies done in Europe, Africa and Asia showed high genetic diversity with no correlation between genotypes and clinical features, but contributed to a better understanding of the epidemiology of the disease. More than 70 genotypes have been described. No similar assessment of T. whipplei in the USA and the Caribbean has been performed. In this study, we describe genetic analysis of DNA from histopathological samples obtained from 30 patients from the Americas with Whipple disease and compare the genotypes with those previously identified. Complete genotypes were obtained from 18 patients (60%). Only 4 genotypes were previously described, and 14 were newly reported, confirming the diversity of T. whipplei strains.
TNFα enhances force generation in airway smooth muscle
Doğan, Murat , Han, Young‐Soo , Delmotte, P. , Sieck, Gary C. , Delmotte, Philippe , Han, Young-Soo, Sieck, Gary

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | April 6, 2017 | Volume: 312 | Issue: 6 | Pages: L994-L1002

10.1152/ajplung.00550.2016 | PMID 28385814 Get It

Airway inflammation is a hallmark of asthma, triggering airway smooth muscle (ASM) hyperreactivity and airway remodeling. TNFα increases both agonist-induced cytosolic Ca2+ concentration ([Ca2+]cyt) and force in ASM. The effects of TNFα on ASM force may also be due to an increase in Ca2+ sensitivity, cytoskeletal remodeling, and/or changes in contractile protein content. We hypothesized that 24 h of exposure to TNFα increases ASM force by changing actin and myosin heavy chain (MyHC) content and/or polymerization. Porcine ASM strips were permeabilized with 10% Triton X-100, and force was measured in response to increasing concentrations of Ca2+ (pCa 9.0 to 4.0) in control and TNFα-treated groups. Relative phosphorylation of the regulatory myosin light chain (p-MLC) and total actin, MLC, and MyHC concentrations were quantified at pCa 9.0, 6.1, and 4.0. Actin polymerization was quantified by the ratio of filamentous to globular actin at pCa 9.0 and 4.0. For determination of total cross-bridge formation, isometric ATP hydrolysis rate at pCa 4.0 was measured using an enzyme-coupled NADH-linked fluorometric technique. Exposure to TNFα significantly increased force across the range of Ca2+ activation but did not affect the intrinsic Ca2+ sensitivity of force generation. The TNFα-induced increase in ASM force was associated with an increase in total actin, MLC, and MyHC content, as well as an increase in actin polymerization and an increase in maximum isometric ATP hydrolysis rate. The results of this study support our hypothesis that TNFα increases force generation in ASM by increasing the number of contractile units (actin-myosin content) contributing to force generation.